Literature DB >> 28905308

An Automated Multidose Synthesis of the Potentiometric PET Probe 4-[18F]Fluorobenzyl-Triphenylphosphonium ([18F]FBnTP).

Christopher M Waldmann1, Adrian Gomez2, Phillip Marchis1, Sean T Bailey3, Milica Momcilovic3, Anthony E Jones1, David B Shackelford3, Saman Sadeghi4.   

Abstract

PURPOSE: The aim of this study was the automated synthesis of the mitochondrial membrane potential sensor 4-[18F]fluorobenzyl-triphenylphosphonium ([18F]FBnTP) on a commercially available synthesizer in activity yields (AY) that allow for imaging of multiple patients. PROCEDURES: A three-pot, four-step synthesis was implemented on the ELIXYS FLEX/CHEM radiosynthesizer (Sofie Biosciences) and optimized for radiochemical yield (RCY), radiochemical purity (RCP) as well as chemical purity during several production runs (n = 24). The compound was purified by solid-phase extraction (SPE) with a Sep-Pak Plus Accell CM cartridge, thereby avoiding HPLC purification.
RESULTS: Under optimized conditions, AY of 1.4-2.2 GBq of [18F]FBnTP were obtained from 9.4 to 12.0 GBq [18F]fluoride in 90-92 min (RCY = 28.6 ± 5.1 % with n = 3). Molar activities ranged from 80 to 99 GBq/μmol at the end of synthesis. RCP of final formulations was > 99 % at the end of synthesis and > 95 % after 8 h. With starting activities of 23.2-33.0 GBq, RCY decreased to 16.1 ± 0.4 % (n = 3). The main cause of the decline in RCY when high amounts of [18F]fluoride are used is radiolytic decomposition of [18F]FBnTP during SPE purification.
CONCLUSIONS: In initial attempts, the probe was synthesized with RCY < 0.6 % when starting activities up to 44.6 GBq were used. Rapid radiolysis of the intermediate 4-[18F]fluorobenzaldehyde and the final product [18F]FBnTP during purification was identified as the main cause for low yields in high-activity runs. Radiolytic decomposition was hindered by the addition of radical scavengers during synthesis, purification, and formulation, thereby improving AY and RCP. The formulated probe in injectable form was synthesized without the use of HPLC and passed all applicable quality control tests.

Entities:  

Keywords:  4-[18F]Fluorobenzyl-triphenylphosphonium; 4-[18F]fluorobenzaldehyde; Antioxidants; Mitochondrial metabolism; Positron emission tomography; Radiolysis; Solid-phase extraction purification; [18F]FBnTP

Mesh:

Substances:

Year:  2018        PMID: 28905308      PMCID: PMC6054454          DOI: 10.1007/s11307-017-1119-1

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  24 in total

1.  18F-fluorobenzyl triphenyl phosphonium: a noninvasive sensor of brown adipose tissue thermogenesis.

Authors:  Igal Madar; Takuro Isoda; Paige Finley; James Angle; Richard Wahl
Journal:  J Nucl Med       Date:  2011-04-15       Impact factor: 10.057

2.  Membrane potential can be determined in individual cells from the nernstian distribution of cationic dyes.

Authors:  B Ehrenberg; V Montana; M D Wei; J P Wuskell; L M Loew
Journal:  Biophys J       Date:  1988-05       Impact factor: 4.033

3.  Characterization of uptake of the new PET imaging compound 18F-fluorobenzyl triphenyl phosphonium in dog myocardium.

Authors:  Igal Madar; Hayden T Ravert; Yong Du; John Hilton; Lana Volokh; Robert F Dannals; James J Frost; Joshua M Hare
Journal:  J Nucl Med       Date:  2006-08       Impact factor: 10.057

Review 4.  Mitochondrial dysfunction in neurodegenerative diseases.

Authors:  Ashu Johri; M Flint Beal
Journal:  J Pharmacol Exp Ther       Date:  2012-06-13       Impact factor: 4.030

5.  Enhanced uptake of [11C]TPMP in canine brain tumor: a PET study.

Authors:  I Madar; J H Anderson; Z Szabo; U Scheffel; P F Kao; H T Ravert; R F Dannals
Journal:  J Nucl Med       Date:  1999-07       Impact factor: 10.057

Review 6.  Targeting mitochondria metabolism for cancer therapy.

Authors:  Samuel E Weinberg; Navdeep S Chandel
Journal:  Nat Chem Biol       Date:  2015-01       Impact factor: 15.040

7.  Studies into radiolytic decomposition of fluorine-18 labeled radiopharmaceuticals for positron emission tomography.

Authors:  Peter J H Scott; Brian G Hockley; Hank F Kung; Rajesh Manchanda; Wei Zhang; Michael R Kilbourn
Journal:  Appl Radiat Isot       Date:  2008-09-07       Impact factor: 1.513

8.  Fully automated synthesis procedure of 4-[18F]fluorobenzaldehyde by commercial synthesizer: amino-oxi peptide labelling prosthetic group.

Authors:  Antonio Speranza; Giovanni Ortosecco; Elena Castaldi; Anna Nardelli; Leonardo Pace; Marco Salvatore
Journal:  Appl Radiat Isot       Date:  2009-04-22       Impact factor: 1.513

9.  Two-step methodology for high-yield routine radiohalogenation of peptides: (18)F-labeled RGD and octreotide analogs.

Authors:  Thorsten Poethko; Margret Schottelius; Georgette Thumshirn; Ulrich Hersel; Michael Herz; Gjermund Henriksen; Horst Kessler; Markus Schwaiger; Hans-Jürgen Wester
Journal:  J Nucl Med       Date:  2004-05       Impact factor: 10.057

Review 10.  Mitochondrial dysfunction and insulin resistance: an update.

Authors:  Magdalene K Montgomery; Nigel Turner
Journal:  Endocr Connect       Date:  2014-11-10       Impact factor: 3.335

View more
  6 in total

1.  An Efficient Automated Radiosynthesis and Bioactivity Confirmation of VMAT2 Tracer [18F]FP-(+)-DTBZ.

Authors:  Chao Zhao; Chunyi Liu; Jie Tang; Yingjiao Xu; Minhao Xie; Zhengping Chen
Journal:  Mol Imaging Biol       Date:  2020-04       Impact factor: 3.488

2.  18F-labeled anti-human CD20 cys-diabody for same-day immunoPET in a model of aggressive B cell lymphoma in human CD20 transgenic mice.

Authors:  Kirstin A Zettlitz; Richard Tavaré; Wen-Ting K Tsai; Reiko E Yamada; Noel S Ha; Jeffrey Collins; R Michael van Dam; John M Timmerman; Anna M Wu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-11-19       Impact factor: 9.236

3.  High-throughput radio-TLC analysis.

Authors:  Jia Wang; Alejandra Rios; Ksenia Lisova; Roger Slavik; Arion F Chatziioannou; R Michael van Dam
Journal:  Nucl Med Biol       Date:  2019-12-17       Impact factor: 2.408

4.  Automation of a Positron-emission Tomography (PET) Radiotracer Synthesis Protocol for Clinical Production.

Authors:  Eric Schopf; Christopher M Waldmann; Jeffrey Collins; Christopher Drake; Roger Slavik; R Michael van Dam
Journal:  J Vis Exp       Date:  2018-10-26       Impact factor: 1.355

Review 5.  The Search for an Alternative to [68Ga]Ga-DOTA-TATE in Neuroendocrine Tumor Theranostics: Current State of 18F-labeled Somatostatin Analog Development.

Authors:  Christopher M Waldmann; Andreea D Stuparu; R Michael van Dam; Roger Slavik
Journal:  Theranostics       Date:  2019-02-14       Impact factor: 11.556

6.  Development and preclinical evaluation of novel fluorinated ammonium salts for PET myocardial perfusion imaging.

Authors:  Ofer Shamni; Hilbert Grievink; Netanel Kolevzon; Seweryn Krajewski; Lukasz Steczek; Ella Meltzer; Shimon Yitshak; Eyal Mishani; Galith Abourbeh
Journal:  Sci Rep       Date:  2021-10-04       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.